Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | POLB | P06746 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | GALR2 | O43603 | 1/20 | 0.41 |
| ▸ | MITF | O75030 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | XBP1 | P17861 | 1/20 | 0.41 |
| ▸ | CCR6 | P51684 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 7/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4246885 | 0.89 | ALDH1A1 (0.45) | ALDH1A1POLBSMN1; SMN2LMNAGALR2 | |
| SCHEMBL4073798 | 0.87 | ALDH1A1 (0.43) | ALDH1A1POLBSMN1; SMN2LMNAGALR2 | |
| SCHEMBL574989 | 0.84 | ALDH1A1 (0.49) | ALDH1A1POLBSMN1; SMN2LMNAGALR2 | |
| SCHEMBL30846439 | 0.84 | ALDH1A1 (0.49) | ALDH1A1POLBSMN1; SMN2LMNAGALR2 | |
| SCHEMBL27314724 | 0.84 | ALDH1A1 (0.49) | ALDH1A1POLBSMN1; SMN2LMNAGALR2 | |
| SCHEMBL4067929 | 0.83 | MEN1 (0.42) | ALDH1A1POLBSMN1; SMN2HPGDKDM4E | |
| SCHEMBL17042260 | 0.82 | NPSR1 (0.55) | ALDH1A1POLBSMN1; SMN2LMNAHPGD | |
| SCHEMBL14031475 | 0.82 | ALDH1A1 (0.47) | ALDH1A1POLBSMN1; SMN2LMNAGALR2 | |
| SCHEMBL4497497 | 0.82 | ALDH1A1 (0.47) | ALDH1A1POLBSMN1; SMN2HSP90AA1HPGD | |
| SCHEMBL15413264 | 0.81 | KDM4E (0.45) | ALDH1A1POLBHPGDKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101282973-A | Imidazopyridine derivatives as cannabinoid receptor ligands | GLAXO GROUP LTD (GB) | 2008-10-08 | — | — | CN | disclosed |
| WO-2008116816-A1 | COMBINATION OF CB2 LIGAND AND PARACETAMOL | GLAXO GROUP LIMITED (GB) | 2008-10-02 | — | — | WO | disclosed |
| US-20080221097-A1 | Imidazopyridine Derivatives as Cannabinoid Receptor Ligands | GLAXO GROUP LIMITED | 2008-09-11 | — | — | US | disclosed |
| US-20080221097-A1 | Imidazopyridine Derivatives as Cannabinoid Receptor Ligands | GLAXO GROUP LIMITED | 2008-09-11 | — | — | US | disclosed |
| EP-1912985-A1 | IMIDAZOPYRIDINE DERIVATIVES AS CANNABINOID RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007017237-A1 | IMIDAZOPYRIDINE DERIVATIVES AS CANNABINOID RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221097-A1 | Imidazopyridine Derivatives as Cannabinoid Receptor Ligands | CNR1, CNR2, TRPV1 | ALDH1A1 3269/4885POLB 4206/4885SMN1; SMN2 2518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.